DONALD SMALL, M.D.
Osteopathic Medicine at Wolfe St, Baltimore, MD
License number
Maryland D35467
Category
Osteopathic Medicine
Type
Medical Oncology
Address
Address
600 N Wolfe St, Baltimore, MD 21287
Phone
(410) 955-6132
Personal information
See more information about DONALD SMALL at radaris.comName
Address
Phone
22198 Mockingbird Ct, Great Mills, MD 20634
22198 Mockingbird Ct, Great Mills, MD 20634
8419 Stevenson Rd, Pikesville, MD 21208
319 Rambling Ridge Ct, Pasadena, MD 21122
1212 Viking Dr N, Arnold, MD 21012
Organization information
See more information about DONALD SMALL at bizstanding.comDonald Small MD,PHD
600 N Wolfe St, Baltimore, MD 21287
Industry:
Pediatric Oncologist, Internist
Phone:
(410) 955-2000 (Phone)
Donald Small
Donald Small MD
1650 Orleans St #251, Baltimore, MD 21287
Categories:
Pediatrics Physicians & Surgeons
Phone:
(410) 614-0994 (Phone)
Professional information
Dr. Donald Small, Baltimore MD - MD (Doctor of Medicine)
Specialties:
Pediatric Hematology & Oncology
Address:
Johns Hopkins University PED ONC
1650 Orleans St, Baltimore 21287
(410) 614-0994 (Phone)
1650 Orleans St, Baltimore 21287
(410) 614-0994 (Phone)
Certifications:
Pediatric Oncology & Pediatric Hematology, 2002, Pediatrics, 1991
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Johns Hopkins University PED ONC
1650 Orleans St, Baltimore 21287
The Johns Hopkins Hospital
1800 Orleans St, Baltimore 21287
1650 Orleans St, Baltimore 21287
The Johns Hopkins Hospital
1800 Orleans St, Baltimore 21287
Education:
Medical School
Johns Hopkins University School Of Medicine
Graduated: 1985
Johns Hopkins Hospital
Johns Hopkins University School Of Medicine
Graduated: 1985
Johns Hopkins Hospital
Professor At Johns Hopkins School Of Medicine
Position:
Professor at Johns Hopkins School of Medicine
Location:
Baltimore, Maryland Area
Industry:
Research
Work:
Johns Hopkins School of Medicine
-
Professor
Flt3 Inhibitors For Immune Suppression
US Patent:
2009005, Feb 26, 2009
Filed:
Jul 14, 2005
Appl. No.:
11/632924
Inventors:
Donald Small - Baltimore MD, US
Katharine A. Whartenby - Baltimore MD, US
Drew Pardoll - Brookeville MD, US
Katharine A. Whartenby - Baltimore MD, US
Drew Pardoll - Brookeville MD, US
Assignee:
THE JOHN HOPKINS UNIVERSITY - Baltimore MD
International Classification:
A61K 31/7056, C12N 5/06, C12N 15/87, A01K 67/027, C12Q 1/02
US Classification:
514 43, 435375, 435455, 800 13, 435 29
Abstract:
New methods are provided for suppressing the immune system and for treating immune related disorders. Therapies of the invention include administration of an FLT3 inhibitor compound to a subject in need thereof, such as a subject suffering from organ rejection, bone marrow transplant rejection, acquired immune deficiency syndrome, arthritis, aplastic anemia, graft-versus-host disease, Graves' disease, established experimental allergic encephalitomyelitis, multiple sclerosis, lupus, or a neurological disorder. Methods are also provided for screening therapeutic agents for treating immune disorders, including the use of a mouse having an elevated level of FLT3 receptor activity.
Antisense Oligonucleotides Specific For Stk-1 And Method For Inhibiting Expression Of The Stk-1 Protein
US Patent:
5618709, Apr 8, 1997
Filed:
Jan 14, 1994
Appl. No.:
8/183211
Inventors:
Alan M. Gewirtz - Philadelphia PA
Donald Small - Baltimore MD
Curt I. Civin - Baltimore MD
Donald Small - Baltimore MD
Curt I. Civin - Baltimore MD
Assignee:
University of Pennsylvania - Philadelphia PA
The Johns Hopkins University - Baltimore MD
The Johns Hopkins University - Baltimore MD
International Classification:
C12N 1500, C07H 2104
US Classification:
4351723
Abstract:
Oligonucleotides are provided having a nucleotide sequence complementary to at least a portion of the mRNA transcript of the STK-1 gene. These "antisense" oligonucleotides are hybridizable to the STK-1 mRNA transcript. Such oligonucleotides are useful in treating neoplastic diseases characterized by activation of STK-1 gene expression. The oligonucleotides are also useful as bone marrow purging agents in the treatment of leukemia and metastasized neoplasms.
Protein Tyrosine Kinase, Jak3
US Patent:
5916792, Jun 29, 1999
Filed:
Jan 6, 1998
Appl. No.:
9/003289
Inventors:
Curt I. Civin - Baltimore MD
Donald Small - Baltimore MD
Meredith G. Safford - Baltimore MD
Donald Small - Baltimore MD
Meredith G. Safford - Baltimore MD
Assignee:
The Johns Hopkins University School of Medicine - Baltimore MD
International Classification:
C07K 14435, C12N 912
US Classification:
435194
Abstract:
A novel protein tyrosine kinase, JAK3, and a polynucleotide sequence encoding JAK3 polypeptide are disclosed herein. JAK3 is a new member of the JAK family of protein tyrosine kinases which are important in regulation of cellular proliferation and differentiation. Also disclosed are therapeutic methods utilizing JAK3 polypeptide and polynucleotide sequences.
Nucleic Acid Encoding Novel Protein Tyrosine Kinase
US Patent:
5705625, Jan 6, 1998
Filed:
Dec 15, 1994
Appl. No.:
8/357598
Inventors:
Curt I. Civin - Baltimore MD
Donald Small - Baltimore MD
Meredith G. Safford - Baltimore MD
Donald Small - Baltimore MD
Meredith G. Safford - Baltimore MD
Assignee:
The Johns Hopkins University School of Medicine - Baltimore MD
International Classification:
C12N 1509, C12N 1552
US Classification:
536 235
Abstract:
A novel protein tyrosine kinase, JAK3, and a polynucleotide sequence encoding JAK3 polypeptide are disclosed herein. JAK3 is a new member of the JAK family of protein tyrosine kinases which are important in regulation of cellular proliferation and differentiation. Also disclosed are therapeutic methods utilizing JAK3 polypeptide and polynucleotide sequences.
Neutralization Of Flt3 Ligand As A Leukemia Therapy
US Patent:
2013015, Jun 20, 2013
Filed:
Mar 14, 2011
Appl. No.:
13/634439
Inventors:
Mark J. Levis - Phoenix MD, US
Donald Small - Pikesville MD, US
Donald Small - Pikesville MD, US
Assignee:
The Johns Hopkins University - Baltimore MD
International Classification:
A61K 39/395, A61K 31/553, A61K 31/44, A61K 31/496, A61K 31/7068, A61K 31/517, A61K 31/404, A61K 31/7048, A61K 31/704, A61K 31/136, A61K 38/45, A61K 31/5377
US Classification:
4241341, 4241581, 514 196, 4241381
Abstract:
Disclosed herein are methods and compositions for treating leukemia and preventing leukemia relapse related to the administration of agents that inhibit the binding of FLT3 ligand to FLT3.